Synergistic effect of statins and postmenopausal hormone therapy in the prevention of skeletal fractures in elderly women

Pharmacotherapy

Volumn 30, Issue 9, 2010, Pages 879-887

  Bakhireva, Ludmila N ^a,b   Shainline, Michael R ^c   Carter, Shelley ^c   Robinson, Scott ^c   Beaton, Sarah J ^c   Nawarskas, James J ^a   Gunter, Margaret J ^c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c LOVELACE CLINIC FOUNDATION   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Administrative database; Drug interaction; Fractures; Osteoporosis; Postmenopausal hormone therapy; Statins

Indexed keywords

ANTICONVULSIVE AGENT; ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CORTICOSTEROID; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; DRUG POTENTIATION; ELDERLY CARE; FEMALE; FOREARM FRACTURE; HIP FRACTURE; HORMONAL THERAPY; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; SPINE FRACTURE; WRIST FRACTURE;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COMORBIDITY; DRUG SYNERGISM; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRACTURES, BONE; HIP FRACTURES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MIDDLE AGED; RISK FACTORS;

EID: 77956149136     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.9.879     Document Type: Article

References (60)

1. National Osteoporosis Foundation. Fast facts on osteoporosis, 2008. Available from http://www.nof.org/professionals/Fast-Facts-Osteoporosis.pdf. Accessed May 5, 2009.
2. Holroyd C, Cooper C, Dennison E. Epidemiology of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008;22:671-85.
3. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82. (Pubitemid 29126875)
4. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993;91:1800-9.
5. Watson KE, Bostrom K, Ravindranath R, Lam T, Norton B, Demer LL. TGF-beta-1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest 1994;93:2106-13.
6. Kostis JB. The importance of managing hypertension and dyslipidemia to decrease cardiovascular disease. Cardiovasc Drugs Ther 2007;21:297-309. (Pubitemid 47387466)
7. Rizzo M, Rini GB. Statins, fracture risk, and bone remodeling: what is true? Am J Med Sci 2006;332:55-60.
8. Jadhav SB, Jain GK. Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol 2006;58:3-18.
9. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-9.
10. Bauer DC. HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int 2003;14:273-82.
11. Woo JT, Kasai S, Stern PH, Nagai K. Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts. J Bone Miner Res 2000;15:650-62. (Pubitemid 30174019)
12. Skoglund B, Forslund C, Aspenberg P. Simvastatin improves fracture healing in mice. J Bone Miner Res 2002;17:2004-8.
13. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 2001;21:1636-41.
14. von Stechow D, Fish S, Yahalom D, et al. Does simvastatin stimulate bone formation in vivo? [online exclusive article]. BMC Musculoskelet Disord 2003;4:8. Available from http://www.biomedcentral.com/1471-2474/4/8.
15. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-10. (Pubitemid 30422037)
16. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000;283:3211-16.
17. Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl- coenzyme A reductase and risk of fracture among older women. Lancet 2000;355:2185-8.
18. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. Statin use, bone mineral density, and fracture risk: Geelong osteoporosis study. Arch Intern Med 2002;162:537-40.
19. Ray WA, Daugherty JR, Griffin MR. Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 2002;8:276-9.
20. Scranton RE, Young M, Lawler E, Solomon D, Gagnon D, Gaziano JM. Statin use and fracture risk: study of a U.S. veterans population. Arch Intern Med 2005;165:2007-12.
21. Reid IR, Hague W, Emberson J, et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial-long-term intervention with pravastatin in ischaemic disease. Lancet 2001;357:509-12.
22. Pedersen TR, Kjekshus J, for the 4S Study Group. Statin drugs and the risk of fracture. JAMA 2000;284:1921-2.
23. LaCroix AZ, Cauley JA, Pettinger M, et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the women's health initiative observational study. Ann Intern Med 2003;139:97-104.
24. Bauer DC, Mundy GR, Jamal SA, et al. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004;164:146-52.
25. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 2007;40:1581-7. (Pubitemid 46779004)
26. Toh S, Hernandez-Diaz S. Statins and fracture risk: a systematic review. Pharmacoepidemiol Drug Saf 2007;16:627-40.
27. Bone HG, Kiel DP, Lindsay RS, et al. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab 2007;92:4671-7.
28. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005;19:117-25.
29. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998;19:26-37. (Pubitemid 28094090)
30. Wierzbicki AS. Synthetic statins: more data on newer lipid-lowering agents. Curr Med Res Opin 2001;17:74-7.
31. Furberg CD. Natural statins and stroke risk. Circulation 1999;99:185-8.
32. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80.
33. Bakhireva LN, Barrett-Connor EL, Laughlin GA, Kritz- Silverstein D. Differences in association of bone mineral density with coronary artery calcification in men and women: the Rancho Bernardo study. Menopause 2005;12:691-8.
34. Etminan M. Pharmacoepidemiology. II: the nested case-control study - a novel approach in pharmacoepidemiologic research. Pharmacotherapy 2004;24:1105-9.
35. Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med 2006;119:S3-11.
36. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7.
37. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12.
38. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002;42:963-70.
39. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003;2:517-26.
40. Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol 2000;29:891-8.
41. Needham DM, Scales DC, Laupacis A, Pronovost PJ. A systematic review of the Charlson comorbidity index using Canadian administrative databases: a perspective on risk adjustment in critical care research. J Crit Care 2005;20:12-19.
42. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19.
43. Buechley RW. A reproducible method of counting persons of Spanish surname. Am Statis Assoc J 1961;56:88-97.
44. Frost FJ, Tollestrup K, Trinkaus KM, et al. Mammography screening and breast cancer tumor size in female members of a managed care organization. Cancer Epidemiol Biomarkers Prev 1998;7:585-9. (Pubitemid 28323885)
45. Gallagher JC, Rapuri PB, Haynatzki G, Detter JR. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab 2002;87:4914-23.
46. Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:875-83.
47. De Leo V, Morgante G, la Marca A, Lanzetta D, Cobellis L, Petraglia F. Combination of statins and hormone replacement therapy in postmenopausal women is associated with increased bone mineral density. Gynecol Endocrinol 2003;17:329-32.
48. Balasch J. Sex steroids and bone: current perspectives. Hum Reprod Update 2003;9:207-22. (Pubitemid 36827059)
49. Bakhireva LN, Barrett-Connor E, Kritz-Silverstein D, Morton DJ. Modifiable predictors of bone loss in older men: a prospective study. Am J Prev Med 2004;26:436-42.
50. Herrington DM, Vittinghoff E, Lin F, et al. Statin therapy, cardiovascular events, and total mortality in the heart and estrogen/progestin replacement study (HERS). Circulation 2002;105:2962-7.
51. Koh KK, Schenke WH, Waclawiw MA, Csako G, Cannon RO III. Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. Circulation 2002;105:1531-3. (Pubitemid 34297625)
52. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T. Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 2001;110:584-7.
53. Rejnmark L, Olsen ML, Johnsen SP, Vestergaard P, Sorensen HT, Mosekilde L. Hip fracture risk in statin users: a population-based Danish case-control study. Osteoporos Int 2004;15:452-8.
54. Adami S, Braga V, Gatti D. Association between bone mineral density and serum lipids in men. JAMA 2001;286:791-2.
55. Adami S, Braga V, Zamboni M, et al. Relationship between lipids and bone mass in 2 cohorts of healthy women and men. Calcif Tissue Int 2004;74:136-42.
56. Poli A, Bruschi F, Cesana B, Rossi M, Paoletti R, Crosignani PG. Plasma low-density lipoprotein cholesterol and bone mass densitometry in postmenopausal women. Obstet Gynecol 2003;102:922-6.
57. von Muhlen D, Safii S, Jassal SK, Svartberg J, Barrett-Connor E. Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo study. Osteoporos Int 2007;18:1337-44. (Pubitemid 47389466)
58. Samelson EJ, Cupples LA, Hannan MT, et al. Long-term effects of serum cholesterol on bone mineral density in women and men: the Framingham osteoporosis study. Bone 2004;34:557-61.
59. Perez-Castrillon JL, Abad L, Vega G, et al. Effect of atorvastatin on bone mineral density in patients with acute coronary syndrome. Eur Rev Med Pharmacol Sci 2008;12:83-8. (Pubitemid 351850041)
60. Gunter MJ, Beaton SJ, Brenneman SK, Chen YT, Abbott TA III, Gleeson JM. Management of osteoporosis in women aged 50 and older with osteoporosis-related fractures in a managed care population. Dis Manag 2003;6:83-91.